Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.63) earnings per share for the quarter, hitting the consensus estimate of ($0.63), FiscalAI reports.
Artiva Biotherapeutics Price Performance
Shares of NASDAQ:ARTV opened at $11.27 on Friday. The business’s fifty day moving average price is $9.36 and its two-hundred day moving average price is $7.74. Artiva Biotherapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $14.53. The stock has a market capitalization of $278.59 million, a price-to-earnings ratio of -3.42 and a beta of 2.16.
Insiders Place Their Bets
In other news, Director Ra Capital Management, L.P. bought 6,510,416 shares of Artiva Biotherapeutics stock in a transaction dated Monday, May 11th. The shares were bought at an average price of $11.52 per share, for a total transaction of $74,999,992.32. Following the purchase, the director owned 15,203,995 shares of the company’s stock, valued at approximately $175,150,022.40. This trade represents a 74.89% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Corp. Gc bought 1,085,069 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $11.52 per share, for a total transaction of $12,499,994.88. Following the acquisition, the insider owned 4,391,969 shares in the company, valued at $50,595,482.88. The trade was a 32.81% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 9,907,958 shares of company stock valued at $107,688,019 and have sold 53,040 shares valued at $477,890. 21.40% of the stock is currently owned by company insiders.
Institutional Trading of Artiva Biotherapeutics
Analysts Set New Price Targets
ARTV has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Wedbush upped their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $39.00.
Read Our Latest Analysis on Artiva Biotherapeutics
Artiva Biotherapeutics Company Profile
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Stories
- Five stocks we like better than Artiva Biotherapeutics
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
- MarketBeat Week in Review – 08/03 – 08/07
- Datadog’s Drop Says More About Expectations Than Earnings
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
